中华实验和临床感染病杂志（电子版）
中華實驗和臨床感染病雜誌（電子版）
중화실험화림상감염병잡지（전자판）
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL INFECTIOUS DISEASES(ELECTRONIC VERSION)
2015年
4期
510-512
,共3页
鲍曼不动杆菌%耐药性%标本来源
鮑曼不動桿菌%耐藥性%標本來源
포만불동간균%내약성%표본래원
Acinetobacter baumannii%Resistance%Specimen source
目的：动态监测院内分离的鲍曼不动杆菌对临床常用抗菌药物耐药率的变化及分布，为院内感染控制提供理论依据。方法用WHONET 5.6对2012年1月至2014年12月山东省泰安市中心医院临床分离的鲍曼不动杆菌对亚胺培南等13种抗菌药物的耐药性及分布进行分析。结果2012年分离的616株鲍曼不动杆菌对亚胺培南等13种抗菌药物的耐药率（52.9%～94.0%）高于2013年分离的536株鲍曼不动杆菌对亚胺培南等13种抗菌药物的耐药率（37.7%～70.1%）。2014年分离的421株鲍曼不动杆菌对左旋氧氟沙星和妥布霉素的耐药率高于2013年分离的鲍曼不动杆菌对左旋氧氟沙星和妥布霉素的耐药率，但2014年分离的鲍曼不动杆菌对其余11种抗菌药物的耐药率（37.2%～65.6%）低于2013年分离的鲍曼不动杆菌的耐药率。院内3年间分离的鲍曼不动杆菌88.4%～92.5%的标本来源于痰液。结论3年间本院临床分离的鲍曼不动杆菌对多数常用抗菌药物的耐药率逐年下降。加强对多重耐药鲍曼不动杆菌的感染控制，可预防和减少院内多重耐药鲍曼不动杆菌的产生和传播。
目的：動態鑑測院內分離的鮑曼不動桿菌對臨床常用抗菌藥物耐藥率的變化及分佈，為院內感染控製提供理論依據。方法用WHONET 5.6對2012年1月至2014年12月山東省泰安市中心醫院臨床分離的鮑曼不動桿菌對亞胺培南等13種抗菌藥物的耐藥性及分佈進行分析。結果2012年分離的616株鮑曼不動桿菌對亞胺培南等13種抗菌藥物的耐藥率（52.9%～94.0%）高于2013年分離的536株鮑曼不動桿菌對亞胺培南等13種抗菌藥物的耐藥率（37.7%～70.1%）。2014年分離的421株鮑曼不動桿菌對左鏇氧氟沙星和妥佈黴素的耐藥率高于2013年分離的鮑曼不動桿菌對左鏇氧氟沙星和妥佈黴素的耐藥率，但2014年分離的鮑曼不動桿菌對其餘11種抗菌藥物的耐藥率（37.2%～65.6%）低于2013年分離的鮑曼不動桿菌的耐藥率。院內3年間分離的鮑曼不動桿菌88.4%～92.5%的標本來源于痰液。結論3年間本院臨床分離的鮑曼不動桿菌對多數常用抗菌藥物的耐藥率逐年下降。加彊對多重耐藥鮑曼不動桿菌的感染控製，可預防和減少院內多重耐藥鮑曼不動桿菌的產生和傳播。
목적：동태감측원내분리적포만불동간균대림상상용항균약물내약솔적변화급분포，위원내감염공제제공이론의거。방법용WHONET 5.6대2012년1월지2014년12월산동성태안시중심의원림상분리적포만불동간균대아알배남등13충항균약물적내약성급분포진행분석。결과2012년분리적616주포만불동간균대아알배남등13충항균약물적내약솔（52.9%～94.0%）고우2013년분리적536주포만불동간균대아알배남등13충항균약물적내약솔（37.7%～70.1%）。2014년분리적421주포만불동간균대좌선양불사성화타포매소적내약솔고우2013년분리적포만불동간균대좌선양불사성화타포매소적내약솔，단2014년분리적포만불동간균대기여11충항균약물적내약솔（37.2%～65.6%）저우2013년분리적포만불동간균적내약솔。원내3년간분리적포만불동간균88.4%～92.5%적표본래원우담액。결론3년간본원림상분리적포만불동간균대다수상용항균약물적내약솔축년하강。가강대다중내약포만불동간균적감염공제，가예방화감소원내다중내약포만불동간균적산생화전파。
Objective To monitoring dynamicly the distribution and drug resistances of clinical isolated Acinetobacter baumannii to the common antimicrobial, and to provide theoretical basis for nosocomial infection control. Methods The distribution and drug resistances of clinical isolated Acinetobacter baumannii collected from January 2012 to December 2014 to 13 antibacterial including imipenem were analyzed by WHONET 5.6, retrospectively. Results The drug resistances rates (52.9%-94.0%) of 616 strains Acinetobacter baumannii isolates collected during 2012 to 13 antibacterial were higher than the drug resistances of 536 strains Acinetobacter baumannii collected during 2013 (37.7%-70.1%). The drug resistances rates of 421 strains Acinetobacter baumannii isolates collected during 2014 to levolfoxacin and tobramycin were higher than those of Acinetobacter baumannii isolates collected during 2013, however the drug resistances rates (37.2%-65.6%) of Acinetobacter baumannii isolates collected during 2014 to the other 11 antibacterial were lower than that of Acinetobacter baumannii isolates collected during 2013. Among the Acinetobacter baumannii isolates collected from 2012 to 2014, 88.4%-92.5% were obtained from sputum. Conclusions The drug resistances of Acinetobacter baumannii isolates collected from 2012 to 2014 to common antibacterial gradually decreased. To strengthen infection control of multidrug resistant Acinetobacter baumannii could prevent and reduce the generation and propagation of multidrug resistant Acinetobacter baumannii.
